At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,306 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Placebo 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Double-dummy, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, Compared to Placebo and Etanercept, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis
In Brief
A Phase 3 clinical trial evaluating Placebo, secukinumab (AIN457), and 1 other intervention for Chronic Plaque Psoriasis. Completed, enrolled 1,306 participants across 152 sites in 23 countries.
Detailed Summary
This study will assess the safety and efficacy of secukinumab compared to placebo and etanercept in patients that have moderate to severe, chronic, plaque-type psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plaque Psoriasis
CountriesArgentina, Australia, Belgium, Canada, Colombia, Egypt, Finland, France, Germany, Guatemala, Hungary, Iceland, India, Italy, Philippines, Poland, Romania, Singapore, South Korea, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartJun 2011
Primary CompletionJul 2013
TodayJul 2026
First PostedMay 23, 2011
Enrollment StartJun 1, 2011
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 15.1 years ago
Interventions
Placebodrug
Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept
secukinumab (AIN457)drug
secukinumab (AIN457) 150mg or 300mg subcutaneous
etanerceptdrug
etanercept 50mg subcutaneous